Even IL-6 blockade in cancer patients treated with immune checkpoint blockade is viewed as a win-win strategy because combined IL-6 blockade and immune checkpoint blockade abrogates immunotherapy toxicity and promotes tumor immunity (58). Here, IL6 is linked to neoplasm.